Allium Financial Advisors, LLC Exelixis, Inc. Transaction History
Allium Financial Advisors, LLC
- $110 Billion
- Q1 2025
A detailed history of Allium Financial Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Allium Financial Advisors, LLC holds 6,866 shares of EXEL stock, worth $273,541. This represents 0.23% of its overall portfolio holdings.
Number of Shares
6,866Holding current value
$273,541% of portfolio
0.23%Shares
1 transactions
Others Institutions Holding EXEL
# of Institutions
590Shares Held
253MCall Options Held
1.15MPut Options Held
1.13M-
Black Rock Inc. New York, NY33.5MShares$1.33 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.17 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$934 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$609 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$455 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.8B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...